Company Overview
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Recent Developments
- Dec 2025 Revenue of $2.80M (-38.2% YoY); net profit $-115.18M.
- Trailing 12 Months Year-on-year growth — revenue -46.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -21.3%, profit CAGR -3.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -21.31% |
| 1 Year: | -46.40% |
Compounded Profit Growth
| 5 Years: | -3.27% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +194.23% |
| 6 Months: | +132.99% |
| 3 Months: | +21.43% |
| 1 Month: | -11.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)48.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -21.3% CAGR over 5 years.
- Earnings shrank at -3.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABSI Absci Corporation R2KR3KPHARMA | 9.18 | -11.62 | $1.58B | 0.00% | -59.37% | -57.72% | -21.31% | -3.27% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 564.00K | 916.00K | 1.06M | 728.00K | 1.54M | 819.00K | 1.00M | 2.37M | 1.27M | 3.37M | 744.00K | 898.00K | 1.27M | - | - | 1.18M | 593.00K | 378.00K | 650.00K | 215.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.91M | 31.99M | 30.53M | 36.79M | 31.06M |
| Operating Income | - | -2.81M | -3.36M | -11.15M | -16.69M | -21.14M | -28.80M | -28.89M | -27.97M | -24.48M | -42.99M | -23.30M | -23.50M | -26.72M | - | - | -27.73M | -31.39M | -30.15M | -36.14M | -30.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.20M | -27.38M | -25.71M | -26.87M | -26.84M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.00K | 56.00K | 45.00K | 29.00K | 18.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.35M | -30.44M | -28.60M | -29.72M | -29.58M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.00K | 131.00K | 104.00K | -162.00K | 18.00K |
| Net Income | -2.66M | -3.01M | -3.75M | -10.96M | -41.20M | -23.63M | -29.49M | -28.68M | -27.26M | -23.36M | -41.67M | -21.99M | -21.98M | -24.75M | - | - | -26.35M | -30.57M | -28.71M | -29.56M | -29.60M |
| Diluted EPS | - | -1.12 | -0.85 | -0.70 | -2.39 | -0.33 | -0.33 | -0.32 | -0.30 | -0.26 | -0.45 | -0.24 | -0.22 | -0.22 | - | - | -0.21 | -0.24 | -0.20 | -0.20 | -0.19 |
| R&D Expense | - | 2.25M | 2.69M | 7.05M | 11.04M | 10.73M | 15.83M | 16.24M | 15.53M | 12.66M | 12.11M | 11.03M | 12.24M | 15.26M | 17.98M | - | 16.36M | 20.46M | 19.25M | - | 19.27M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.78M | - | 5.75M | 5.72M | 4.53M | 2.80M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 112.50M | 99.90M | 113.42M | 128.22M |
| Operating Income | -13.30M | - | -106.75M | -94.18M | -108.89M | -125.42M |
| EBITDA | - | - | -91.29M | -95.46M | -89.08M | -103.16M |
| Interest Expense | - | - | 972.00K | 1.01M | 565.00K | 209.00K |
| Pretax Income | - | - | -105.36M | -110.47M | -103.04M | -115.11M |
| Tax Provision | - | - | -461.00K | 100.00K | 70.00K | 69.00K |
| Net Income | -14.35M | - | -104.90M | -110.57M | -103.11M | -115.18M |
| Diluted EPS | -3.19 | - | -1.15 | -1.20 | -0.94 | -0.84 |
| R&D Expense | 11.45M | 44.59M | 58.91M | 48.07M | 63.86M | 81.42M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 88.57M | - | 321.01M | 217.30M | 213.61M | 216.30M |
| Current Assets | - | - | - | 186.86M | 120.58M | 133.83M | 149.57M |
| Cash & Equivalents | - | 69.87M | - | 59.95M | 72.36M | 41.21M | 20.02M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 2.19M | 0 | - |
| Total Liabilities | - | 21.56M | - | 46.59M | 41.12M | 34.48M | 26.85M |
| Current Liabilities | - | 10.10M | - | 30.27M | 29.56M | 28.66M | 22.77M |
| Long Term Debt | - | - | 1.12M | 7.98M | 4.66M | 1.26M | - |
| Total Debt | - | - | - | 22.98M | 15.88M | 10.03M | 5.30M |
| Total Equity | -41.16M | -89.43M | - | 274.41M | 176.18M | 179.13M | 189.45M |
| Shares Outstanding | - | - | - | 92.41M | 93.09M | 115.36M | 151.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.97M | - | -81.34M | -64.64M | -72.40M | -92.92M |
| Investing Cash Flow | -2.17M | - | -126.98M | 81.94M | -41.58M | -50.16M |
| Financing Cash Flow | 70.97M | - | 5.24M | -4.48M | 82.53M | 105.95M |
| Capital Expenditure | -2.18M | - | -16.18M | -860.00K | -404.00K | -1.11M |
| Free Cash Flow | -13.15M | - | -97.51M | -65.50M | -72.81M | -94.03M |
| Net Change in Cash | - | - | -203.08M | 12.82M | -31.45M | -37.14M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -278.3% | - | -1,857.5% | -1,647.1% | -2,401.6% | -4,479.2% |
| Net Margin % | -300.3% | - | -1,825.4% | -1,933.6% | -2,274.1% | -4,113.7% |
| ROE % | 16.0% | - | -38.2% | -62.8% | -57.6% | -60.8% |
| ROCE % | -16.9% | - | -36.7% | -50.2% | -58.9% | -64.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.81% | 25.41M | $258.17M |
| 2 | ARK Investment Management, LLC | 7.53% | 12.93M | $131.32M |
| 3 | Blackrock Inc. | 7.09% | 12.18M | $123.70M |
| 4 | State Street Corporation | 4.72% | 8.10M | $82.27M |
| 5 | Ameriprise Financial, Inc. | 4.07% | 6.99M | $71.04M |
| 6 | Redmile Group, LLC | 3.93% | 6.74M | $68.48M |
| 7 | Vanguard Capital Management LLC | 3.57% | 6.12M | $62.21M |
| 8 | Advanced Micro Devices Inc | 3.33% | 5.71M | $58.06M |
| 9 | Adage Capital Partners GP L.L.C. | 3.32% | 5.70M | $57.96M |
| 10 | Two Sigma Investments, LP | 3.20% | 5.49M | $55.81M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABSI
Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop
Absci has posted very strong multi year share gains, and the jump in market value now raises a simple question for you as an investor. Is the current price still grounded in what the business has built on its balance sheet, or has it moved …
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will …
Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?
Absci (ABSI) is back in focus after management outlined fresh details for its planned global Phase 2 STORYLINE trial of ABS-201 in endometriosis, giving investors a clearer read on this pipeline project. After the ABS-201 STORYLINE update, …
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK…
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Absci has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$9.82 level is supported by the company’s book value. For anyone looking at the stock today, the key issue is how that accounting b…
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will…
ABSI — Frequently Asked Questions
What is the current share price of Absci Corporation (ABSI)?
As of 2026-10-23 16:27 PDT, Absci Corporation (ABSI) trades at $9.18 on NasdaqGS. Its 52-week range is $2.30 to $11.62.
What is the market capitalisation of ABSI?
Absci Corporation (ABSI) has a market capitalisation of $1.58B on NasdaqGS.
What is the P/E ratio of ABSI?
ABSI trades at a trailing price-to-earnings (P/E) ratio of -11.62. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.08.
What is the return on equity (ROE) of ABSI?
ABSI has a return on equity (ROE) of -57.72%. Its return on capital employed (ROCE) is -59.37%.
Is ABSI a good stock to buy?
This page provides a data-driven analysis of Absci Corporation (ABSI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.